207514-59-8

Basic information

• Product Name: [4-((S)-2-tert-Butoxycarbonylamino-3-naphthalen-1-yl-propionylamino)-phenyl]-acetic acid benzyl ester
• CAS NO: 207514-59-8
• Molecular Weight: 538.643
• Mol File: 207514-59-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [4-((S)-2-tert-Butoxycarbonylamino-3-naphthalen-1-yl-propionylamino)-phenyl]-acetic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [4-((S)-2-tert-Butoxycarbonylamino-3-naphthalen-1-yl-propionylamino)-phenyl]-acetic acid benzyl ester(207514-59-8)
• EPA Substance Registry System: [4-((S)-2-tert-Butoxycarbonylamino-3-naphthalen-1-yl-propionylamino)-phenyl]-acetic acid benzyl ester(207514-59-8)

Safety Data

• Hazardous Substances Data: 207514-59-8(Hazardous Substances Data)

Upstream product

• 55447-00-2 (S)-2-tert-butoxycarbonylamino-3-naphthalen-1-yl-propionic acid 
• 3254-97-5 4-aminophenyl acetic acid benzyl ester 

Relevant articles and documents

Design of plasma kallikrein inhibitors: Functional and structural requirements of plasma kallikrein inhibitors

The synthetic plasma kallikrein (PK) inhibitor trans-4- aminomethylcyclohexanecarbonylphenylalanine-4-carboxymethylanilide (PKSI- 527) consists of three parts. Each part was replaced by analogues in an attempt to improve the potency and the selectivity of PKSI-527. Among the peptides examined, trans-4-aminomethyl-cyclohexanecarbonylphenylalanine-4- carboxyanilide (peptide 16) inhibited PK with a high selectivity and an IC50 value of 2.7 μM, being as potent as PKSI-527.